Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study

Summary Although epithelial–mesenchymal markers play an important role in prostate cancer (PC), further research is needed to better understand their utility in diagnosis, cancer progression prevention, and treatment resistance prediction. Our study included 111 PC patients who underwent transurethral resection, as well as 16 healthy controls. Reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) was used to examine the expression of E‐cadherin, β‐catenin, and Vimentin. We found that E‐cadherin and β‐catenin were underexpressed in primary PC tissues. E‐cadherin expression was found to be inversely associated with prostate‐specific antigen progression (PSA‐P; serum marker of progression; p = 0.01; |r| = 0.262). Furthermore, the underexpression of two markers, E‐cadherin and β‐catenin, was found to be associated with advanced tumor stage and grade ( p < 0.05). On the other hand, Vimentin was overexpressed in PC patients with a fold change of 2.141, and it was associated with the diagnosis, prognosis, and prediction of treatment resistance to androgen deprivation therapy ( p = 0.002), abiraterone‐acid ( p = 0.001), and taxanes ( p = 0.029). Moreover, the current study highlighted that poor survival could be significantly found in patients who progressed after primary surgery, did not use drugs, and expressed these genes aberrantly. In Cox regression multivariate analysis ( p < 0.05), a positive correlation between the Vimentin marker and coronary heart disease in PC patients was identified ( p = 0.034). In summary, the present study highlights the diagnostic ( p < 0.001), prognostic ( p < 0.001), and therapeutic potential of Vimentin in primary PC ( p < 0.05), as well as its implications for cardiovascular disease. Furthermore, we confirm the potential prognostic value of E‐cadherin and β‐catenin.